| Description | Finafloxacin, a fluoroquinolone antimicrobial agent from a new 8-cyano subclass, is most effective in slightly acidic environments (pH 5.0-6.0), a condition where other fluoroquinolones typically reduce in activity. It selectively targets bacterial type II topoisomerases, such as DNA gyrase and DNA topoisomerase IV, making it suitable for treating serious bacterial infections particularly in acidic contexts, including urinary tract infections (UTIs) and Helicobacter pylori infections. |
| molecular weight | 398.39 |
| Molecular formula | C20H19FN4O4 |
| CAS | 209342-40-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 6.4 mg/mL (16.06 mM), Sonication and heating are recommended. |
| References | 1. McKeage K. Finafloxacin: first global approval. Drugs. 2015 Apr;75(6):687-93. |
| Citations | 1. Kong Y, Geng Z, Jiang G, et al.Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China.Heliyon.2023 |